Understand the source comparison
Best Peptides for Vertigo: Evidence Comparison
Cerebrolysin BDNF/NGF mimetic. Promotes synaptic remodeling in vestibular nuclei Animal studies show 40–60% faster vestibular compensation post-labyrinthectomy 5–10mL IV, 10–20 sessions Strongest evidence for direct vestibular compensation support Dihexa HGF r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/NGF mimetic. Promotes synaptic remodeling in vestibular nuclei
- Animal studies show 40–60% faster vestibular compensation post-labyrinthectomy
- 5–10mL IV, 10–20 sessions
- Strongest evidence for direct vestibular compensation support
- Dihexa
- HGF receptor agonist. Triggers dendritic spine formation and cortical synaptogenesis
- University of Arizona cognitive studies; dose-dependent neuroplasticity
- 0.5–2mg oral or subcutaneous
- High neuroplasticity potential; limited human vestibular data
- P21
- CNTF derivative. Supports neurogenesis and reduces neuroinflammation
- Preclinical models show hippocampal neurogenesis and BBB penetration
- 1–5mg subcutaneous
- Promising for inflammatory vestibular conditions; needs human trials
- Thymalin
- Immune modulation. Reduces IL-6, TNF-alpha; promotes T-reg activity
- Russian clinical data for autoimmune conditions
- 10mg IM, 5–10 day cycles
- Relevant for autoimmune inner ear disease; limited Western research
- MK 677
- GH secretagogue. Elevates IGF-1 for myelination and nerve repair support
- JCEM studies show 40–90% IGF-1 increase at 10–25mg oral
- 10–25mg oral daily
- Indirect vestibular support; well-tolerated long-term
- KPV
- Melanocortin receptor. NF-kB inhibition, anti-inflammatory signaling
- In vitro anti-inflammatory data; no vestibular-specific trials
- 500mcg–2mg subcutaneous
- Mechanistically sound; lacks clinical vertigo research